Tirzepatide-Induced Weight Loss and Normalization of Glycemia With Nerve Regeneration in Type 2 Diabetes: A Case Report

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide 1 (GLP-1) receptor agonist, improves weight, hyperglycemia, hypertension, and hypertriglyceridemia (1), all of which are risk factors for diabetic neuropathy (2). The SURPASS-CVOT trial recently demonstrated that tirzepatide reduces cardiorenal events in patients with type 2 diabetes and atherosclerotic cardiovascular disease (3). Furthermore, a recent real-world analysis demonstrated a reduction in major adverse limb events with tirzepatide (4), suggesting that it may improve neuropathy.